Update on Coronavirus (COVID-19)

See our latest statement here

Dr Peter Scholes

Chief Scientific Officer

Peter has over 20 years’ experience in the pharmaceutical industry. In his role at Quotient Sciences he has been instrumental in identifying and implementing the innovative and flexible benefits of integrating pharmaceutical development and clinical testing in early research. Peter has served as a committee member for the U.K. Controlled Release Society and APS Biopharmaceutics focus group and in 2013 set up a GastroPlus™ user group with industry colleagues as a discussion forum for PBPK modelling and simulation science. In 2010, Peter was named one of PharmaVOICE’s 100 most inspiring people in the life-sciences industry. He was appointed as an Honorary Professor in Pharmaceutical Sciences at Nottingham University in August 2015.

Dr Nutan Gangrade

Global Vice President, Pharmaceutical Sciences

Commercial manufacturing

Clinical trial manufacturing

Nutan has over 25 years' experience within the pharmaceutical industry. Prior to his current role, Nutan served as Senior Director of Formulation Development at QS Pharma and is a founding team member. He has previously held positions at Bristol-Myers Squibb (DuPont Pharmaceuticals Company) and Wyeth-Ayerst Research (American Cyanamid Company). In these positions, he was the CMC lead for several products in various phases of development. Nutan graduated with a Ph.D. in Pharmaceutics from the University of Georgia.

Dr Stuart Mair

Global Vice President, Medical

Stuart has over 15 years’ experience of delivering exploratory clinical studies in the CRO Industry, he has delivered over 100 First in Human studies and is an expert in the design and implementation of exploratory clinical trials from First-in-Human to Proof-of-Concept in patient groups with PD biomarkers. He has advised clients on multiple study types from simple PK, BE and characterisation studies to complex flexible designs with multiple portions delivered under a single protocol.

Andrew Lewis

Vice President, Pharmaceutical Sciences

Translational Pharmaceutics

Clinical trial manufacturing

Formulation development

Andy has over 15 years’ experience in the pharmaceutical and drug delivery industry. He currently leads a team of 120 scientists working on formulation development, clinical manufacturing and pharmaceutical analysis projects. Dr Lewis is dedicated to overcoming drug delivery challenges, including solubility enhancement, controlled release and transmucosal delivery of proteins and peptides. He is a member of the Academy of Pharmaceutical Scientists of Great Britain and is currently Secretary of the Controlled Release Society.

Dr Kieran Crowley

Executive Director, Quotient Sciences

Translational Pharmaceutics

Clinical pharmacology

Kieran has over 15 years’ experience leading Pre-formulation and Formulation Development teams in both innovator and contract manufacturing organisations. His expertise is in selecting and optimising drug delivery systems based on the physicochemical and biopharmaceutics properties of the active ingredient. Oral delivery of poorly soluble compounds is a particular field of experience and interest, in which he has successfully advanced products using hot melt extrusion, nanomilling and lyophilisation. Kieran’s responsibilities at Quotient Sciences include the design and implementation of integrated pharmaceutical and clinical development programs, utilizing Quotient’s ability to manufacture drug products in real-time in response to arising human data.

Nazim Kanji

Executive Director, Pediatric Services

Pediatrics

Formulation development

Nazim has over 25 years’ experience in the Pharmaceutical and Consumer Healthcare Industry. He has worked in product development roles within Boots Pharmaceuticals, Boots Healthcare International and Reckitt Benckiser and has experience of taking products from concept stage through to commercialisation. He was co-owner and director of Co-Formulate, a contract formulation development organisation, which was acquired by Quotient in 2015. In his current role at Quotient Sciences, Nazim works closely with clients to assist with scoping their pediatric development programs and provides on-going technical support to the Quotient product development teams.

John McDermott

Executive Drug Development Consultant

Translational Pharmaceutics

Clinical pharmacology

John has over 15 years industry experience in roles in pharmaceutical sciences with Rhone Poulenc Rorer, Covance and Quotient Sciences, which he joined in 2001. He has been central to the development of Quotient's integrated pharmaceutical and clinical development programs, utilizing our ability to manufacture drug products in real-time in response to arising human data. John's responsibilities at Quotient Sciences include the design and implementation of integrated pharmaceutical and clinical development programs. In addition, John has a significant body of experience in scintigraphic imaging studies for oral and inhaled dosage forms, including the development and validation of radiolabelling methods.

Dr Prasad Challapalli

Director, Formulation Development

Commercial manufacturing

Clinical trial manufacturing

Prasad has over 25 years’ professional experience, with 15 years’ in the CMO industry. Prasad develops and implements suitable workflows to achieve operational excellence in the manufacture of products, and mentors and manages formulation scientists and manufacturing teams. Prior to his current role at Quotient Sciences, Prasad worked at QS Pharma as Director of Formulation Development, and at Patheon, as Manager of Business Development Services and Senior Scientific Leader in the Formulation Process Development Group.

Iain Shaw

Director, 14-C Enabled Drug Development

Translational Pharmaceutics

Clinical pharmacology

Iain has over 20 years drug development experience having previously held early development program management, clinical development and analytical posts in the pharmaceutical industry and contract research organisations. Prior to his current role he was a Program Manager in early drug development at Covance. He has previously held various analytical, project management and clinical development posts in the pharmaceutical, agrochemical and contract research industries. In total he has 30 years industrial experience. Iain’s responsibilities at Quotient Sciences include all 14C clinical activities since April 2009.

Dr Vanessa Zann

Senior Drug Development Consultant

Translational Pharmaceutics

Clinical pharmacology

Vanessa has over 17 years industry experience providing biopharmaceutics support to discovery, development and clinical programs. Vanessa has previous experience at AstraZeneca as a permeability expert working in the Pharmaceutical Development dept. where she lead the global Caco-2 facility for development, liaising with discovery scientists to ensure selection of NCE with appropriate biopharmaceutical properties, introduced the IV microtracer technique and also provided biopharmaceutical support to both Discovery and Development programs. Vanessa joined Quotient Sciences in 2012 and has lead the implementation of Modelling and Simulation and been heavily involved in the Pharmaceutical Sciences in vitro characterisation strategy, as well as designing clinical studies and providing scientific support through clinical study delivery.

Dr Aruna Railkar

Senior Drug Development Consultant

Translational Pharmaceutics

Clinical pharmacology

Formulation development

Aruna has over 25 years of experience in the pharmaceutical industry working at the discovery – development interface, understanding how the physicochemical and biopharmaceutic properties of compounds inform NCE selection and formulation development for preclinical and clinical studies. Her experience includes leading and collaborating with discovery and development teams in characterizing molecular properties, providing critical input for progressing compounds into clinical development, prodrug evaluation, understanding challenges in absorption/exposure and selection of formulation strategies based on compound properties (conventional or enabling).  Other areas of interest are controlled/targeted release dosage forms for NCEs or novel dosage forms for existing drugs (alternate route of administration or improved delivery which can use the 505(b)(2) development pathway).    

Dr Shriram Pathak

Senior Research Fellow, Scientific Consulting

Translational Pharmaceutics

Clinical pharmacology

Formulation development

Shriram is a member of the scientific consulting group at Quotient and has a comprehensive experience in the biopharmaceutical aspects of formulation design and development. He has a thorough understanding of the new technologies in the field of drug absorption modelling and has been involved in the development and optimization of biorelevant tests (dissolution, precipitation, absorption tests) to provide in vitro, in silico and in vivo correlations. Prior to joining Quotient in 2019, Shriram was a member of the modelling and simulations group at Certara, UK, where he was involved in the development of mechanistic modelling tools to inform a rational formulation design. Shriram has previously worked at Dr. Reddy’s Laboratories where his role involved the development of bioequivalent drug products.

Chris Roe

Research Fellow, Scientific Consulting

Translational Pharmaceutics

Clinical pharmacology

Chris joined Quotient in 2015 as a Research Fellow, bringing over 20 years’ experience across pharmaceutical sciences and biopharmaceutics through a series of previous technical and leadership roles at Sanofi, Pfizer, AstraZeneca and Walgreens Boots Alliance. His expertise ranges from early pre‑formulation and biopharmaceutical assessments ensuring appropriate new chemical entity selection, through development of a wide range of dosage forms including preclinical and early clinical inhalation, topical, oral immediate release and modified release formulations, to maintenance and life-cycle management of existing marketed products. Chris’ role at Quotient involves designing science­-­led, robust, clinical study programs which maximise output for clients, in addition to providing scientific support throughout study delivery. Chris holds a Bachelor of Science degree in Medicinal Chemistry from Newcastle University and Postgraduate Certificate in Education from Nottingham Trent University.

Ask Us a Question

With two simple steps we can help you with your drug development challenges.

Simply select the most relevant scientist(s) and submit your question(s).
You can select more than one expert. We will respond within 48 hours.

  • Andrew Lewis

    Vice President, Pharmaceutical Sciences

    Translational Pharmaceutics

    Clinical trial manufacturing

    Formulation development

  • Dr Kieran Crowley

    Executive Director, Quotient Sciences

    Translational Pharmaceutics

    Clinical pharmacology

  • Nazim Kanji

    Executive Director, Pediatric Services

    Pediatrics

    Formulation development

  • John McDermott

    Executive Drug Development Consultant

    Translational Pharmaceutics

    Clinical pharmacology

  • Dr Prasad Challapalli

    Director, Formulation Development

    Commercial manufacturing

    Clinical trial manufacturing

  • Iain Shaw

    Director, 14-C Enabled Drug Development

    Translational Pharmaceutics

    Clinical pharmacology

  • Dr Vanessa Zann

    Senior Drug Development Consultant

    Translational Pharmaceutics

    Clinical pharmacology

  • Dr Aruna Railkar

    Senior Drug Development Consultant

    Translational Pharmaceutics

    Clinical pharmacology

    Formulation development

  • Dr Shriram Pathak

    Senior Research Fellow, Scientific Consulting

    Translational Pharmaceutics

    Clinical pharmacology

    Formulation development

  • Chris Roe

    Research Fellow, Scientific Consulting

    Translational Pharmaceutics

    Clinical pharmacology

Ask your questions here

Would you like to receive further scientific content including case studies, whitepapers and seminar and webinar invitations?
You can find out how we handle your personal information in our privacy policy here.

Your questions will be sent to the following experts:

Dr Peter Scholes

Chief Scientific Officer

Dr Nutan Gangrade

Global Vice President, Pharmaceutical Sciences

Commercial manufacturing

Clinical trial manufacturing

Dr Stuart Mair

Global Vice President, Medical

Andrew Lewis

Vice President, Pharmaceutical Sciences

Translational Pharmaceutics

Clinical trial manufacturing

Formulation development

Dr Kieran Crowley

Executive Director, Quotient Sciences

Translational Pharmaceutics

Clinical pharmacology

Nazim Kanji

Executive Director, Pediatric Services

Pediatrics

Formulation development

John McDermott

Executive Drug Development Consultant

Translational Pharmaceutics

Clinical pharmacology

Dr Prasad Challapalli

Director, Formulation Development

Commercial manufacturing

Clinical trial manufacturing

Iain Shaw

Director, 14-C Enabled Drug Development

Translational Pharmaceutics

Clinical pharmacology

Dr Vanessa Zann

Senior Drug Development Consultant

Translational Pharmaceutics

Clinical pharmacology

Dr Aruna Railkar

Senior Drug Development Consultant

Translational Pharmaceutics

Clinical pharmacology

Formulation development

Dr Shriram Pathak

Senior Research Fellow, Scientific Consulting

Translational Pharmaceutics

Clinical pharmacology

Formulation development

Chris Roe

Research Fellow, Scientific Consulting

Translational Pharmaceutics

Clinical pharmacology

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.